{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:17:32Z","timestamp":1768389452951,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study employed a multidimensional evaluation framework (of efficacy, safety, and costs) to comprehensively assess the value of Chinese patent medicines (CPMs) combined with Western medicine in treating coronary heart disease (CHD) angina pectoris with Qi deficiency and blood stasis pattern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Efficacy analysis was based on a network meta-analysis (NMA) of 24 randomized controlled trials (RCTs). Safety was assessed using a standardized framework that graded adverse events via CTCAE v5.0 and synthesized risk profiles into a Composite Safety Score. A pragmatic Cost-Consequence Analysis (CCA) was employed to synthesize direct daily treatment costs with clinical efficacy rankings (SUCRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The network meta-analysis of 24 RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      = 2,382) showed that CPMs combined with conventional medicine significantly improved clinical efficacy (OR 3.08, 95% CI: 2.46\u20133.85). Dengzhan Shengmai Capsule (SUCRA 88.99%) and Shexiang Tongxin Dropping Pill (SUCRA 75.12%) ranked highest in efficacy. Safety analysis using the Composite Safety Score (CSS) identified Yangxinshi Tablet as having the most favorable profile (CSS = 3), whereas Xintong Granule and Qishen Capsule presented higher risks (CSS = 9) due to hepatotoxicity concerns or data gaps. Cost-consequence analysis revealed distinct value profiles: Yangxinshi Tablet offered the lowest daily cost (CNY 6.24) suitable for cost-minimization; Shexiang Tongxin Dropping Pill (CNY 7.28) provided a balanced cost-efficacy ratio; while Dengzhan Shengmai Capsule (CNY 10.86) represented a premium high-efficacy option. Sensitivity analysis confirmed the robustness of efficacy findings but highlighted cost fluctuations in flexible-dose regimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Specific CPMs, notably Dengzhan Shengmai Capsule (maximal efficacy), Shexiang Tongxin Dropping Pill (balanced value), and Yangxinshi Tablet (cost-minimization), demonstrate significant therapeutic and economic advantages as add-on therapies. Beyond these clinical findings, this study establishes a multidimensional framework aligned with international regulatory standards, serving as a model for the future pharmacoeconomic integration of TCM into global cardiovascular care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1696072","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:30:07Z","timestamp":1768372207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and costs of nine Chinese patent medicines for the treatment of angina pectoris in CHD"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiahui","family":"Sun","sequence":"first","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]},{"name":"City University of Hong Kong","place":["Kowloon, Hong Kong SAR, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixuan","family":"Li","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Ying","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Hu","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naitong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Policy & Pharmacoeconomics Research Center, West China College of Pharmacy, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/03007995.2024.2317433","article-title":"Safety and tolerability of beta-blockers: importance of cardioselectivity","volume":"40","author":"Marti","year":"2024","journal-title":"Curr Med Res Opin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.59556\/japi.72.0704","article-title":"Stable angina pectoris: a review of pathophysiology, diagnosis, and its management","volume":"72","author":"Sharma","year":"2024","journal-title":"J Assoc Phys India."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1053\/j.jvca.2025.03.029","article-title":"Advances in Cardiovascular Pharmacotherapy. II Ivabradine, an Inhibitor of the hyperpolarization-activated cyclic nucleotide-gated channel","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardio Vasc Anest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/jebm.12671","article-title":"Comparative efficacy and safety of different low-dose platelet inhibitors in patients with coronary heart disease: a bayesian network meta-analysis","volume":"17","author":"Li","year":"2024","journal-title":"J Evid Based Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.5551\/jat.RV22024","article-title":"Lipid-lowering Therapy and Coronary Plaque Regression","volume":"31","author":"Ueki","year":"2024","journal-title":"J Atheroscler Thromb."},{"key":"B6","first-page":"1402","article-title":"Effects of Dengzhan Shengmai Capsule combined with antiplatelet drug and statin therapy on platelet function, inflammatory response and lipid metabolism in patients with unstable angina pectoris","volume":"24","author":"Gao","year":"2018","journal-title":"J Hainan Med Univ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.19852\/j.cnki.jtcm.20230506.001","article-title":"Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network meta-analysis","volume":"43","author":"Chao","year":"2023","journal-title":"J Trad Chin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e23194","DOI":"10.1016\/j.heliyon.2023.e23194","article-title":"Comparative efficacy of five traditional Chinese medicine injections for treating heart failure with reduced and mildly reduced ejection fraction: Bayesian network meta-analysis","volume":"10","author":"Zheng","year":"2024","journal-title":"Heliyon."},{"key":"B9","first-page":"22","article-title":"Clinical efficacy of Naoxin Tong Capsule for stable angina with Qi deficiency and blood stasis pattern","volume":"12","author":"Cai","year":"2020","journal-title":"J Clin Res Chin Med."},{"key":"B10","first-page":"19","article-title":"Therapeutic effect of Qishen Yiqi Dropping Pill on coronary heart disease with Qi deficiency and blood stasis syndrome","volume":"36","author":"Chen","year":"2017","journal-title":"Inner Mongolia J Trad Chin Med."},{"key":"B11","first-page":"1255","article-title":"Tongxinluo capsule efficacy on stable angina with Qi deficiency\/blood stasis and left ventricular function impact","volume":"45","author":"Cui","year":"2023","journal-title":"Hebei J Trad Chin Med."},{"key":"B12","first-page":"1065","article-title":"Mechanism of Tongxinluo Capsule for Qi deficiency-blood stasis type CHD angina","volume":"15","author":"Duan","year":"2016","journal-title":"Chin J Difficult Complicat Cases."},{"key":"B13","first-page":"389","article-title":"Qishen Yiqi Dropping Pill combined with Western medicine for CHD angina [J]","volume":"27","author":"Gao","year":"2012","journal-title":"Mod Drugs Clin."},{"key":"B14","volume-title":"Tongxinluo for CHD angina (Qi deficiency-blood stasis) with anxiety\/depression","author":"Gao","year":"2021"},{"key":"B15","first-page":"787","article-title":"Cardiac function improvement with Qishen Yiqi Dropping Pill+Western medicine","volume":"39","author":"Li","year":"2015","journal-title":"Heilongjiang Med J."},{"key":"B16","first-page":"44","article-title":"Qishen Capsule for stable exertional angina: 120-case analysis","volume":"37","author":"Li","year":"2021","journal-title":"Hunan J Trad Chin Med."},{"key":"B17","first-page":"100","article-title":"Yangxinshi efficacy for CHD with Qi deficiency-blood stasis","volume":"12","author":"Lin","year":"2017","journal-title":"World Chin Med."},{"key":"B18","first-page":"257","article-title":"Yangxinshi Tablet for CHD angina with Qi deficiency-blood stasis","volume":"3","author":"Liu","year":"2008","journal-title":"Clin J Chin Med."},{"key":"B19","article-title":"Fufang Dilong Tablet for unstable angina with Qi deficiency-blood stasis","author":"Liu","year":"2018","journal-title":"Nanjing Univ Chin Med."},{"key":"B20","first-page":"58","article-title":"Qishen Capsule+Western medicine for CHD angina","volume":"6","author":"Lu","year":"2013","journal-title":"J Clin Ration Drug Use."},{"key":"B21","first-page":"765","article-title":"Naoxin Tong Capsule efficacy for CHD angina with Qi deficiency-blood stasis","volume":"17","author":"Luo","year":"2019","journal-title":"Chin J Integr Med Cardio-Cerebrovasc Dis."},{"key":"B22","first-page":"62","article-title":"Qishen Capsule+Nicorandil for elderly microvascular angina","volume":"33","author":"Shen","year":"2021","journal-title":"Med J Chin People's Health."},{"key":"B23","first-page":"57","article-title":"Xintong Granules for CHD angina with Qi deficiency-blood stasis","volume":"17","author":"Sun","year":"2019","journal-title":"Chin J Geriatr Care."},{"key":"B24","volume-title":"Fufang Dilong Tablet for stable angina with Qi deficiency-blood stasis","author":"Tian","year":"2018"},{"key":"B25","first-page":"65","article-title":"Qishen Capsule efficacy for CHD angina (Qi deficiency-blood stasis)","volume":"42","author":"Xu","year":"2023","journal-title":"Inner Mongolia J Tradit Chin Med."},{"key":"B26","first-page":"994","article-title":"Shexiang Tongxin Dropping Pill efficacy for CHD angina with Qi deficiency-blood stasis","volume":"26","author":"Zhang","year":"2015","journal-title":"Modern Diagnos Treat."},{"key":"B27","volume-title":"Long-term Yangxinshi Tablet therapy for chronic stable angina","author":"Zhang","year":"2014"},{"key":"B28","first-page":"201","article-title":"Clinical effects of Qishen Capsule for CHD angina","volume":"13","author":"Zhang","year":"2015","journal-title":"Guide Chin Med."},{"key":"B29","first-page":"85","article-title":"Naoxin Tong Capsule efficacy for stable angina with Qi deficiency-blood stasis","volume":"38","author":"Zhao","year":"2022","journal-title":"Chin Commun Doctors."},{"key":"B30","first-page":"44","article-title":"Dengzhan Shengmai Capsule adjuvant therapy for elderly stable angina","volume":"41","author":"Zhong","year":"2020","journal-title":"Yunnan J Trad Chin Med Mat Med."},{"key":"B31","first-page":"95","article-title":"Qishen Yiqi Dropping Pill+Western medicine for CHD angina with Qi deficiency-blood stasis","volume":"16","author":"Zhou","year":"2016","journal-title":"World Latest Med Inform."},{"key":"B32","first-page":"92","article-title":"Clinical efficacy of Tongxinluo Capsule for CHD angina (Qi deficiency-blood stasis type)","volume":"40","author":"Zuo","year":"2020","journal-title":"Drug Res."},{"key":"B33","unstructured":"2017"},{"key":"B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/1099-1050(200101)10:1<39::AID-HEC563>3.0.CO;2-E","article-title":"Theory versus practice:a review of \u201cwillingness-to-pay\u201d in health and health care","volume":"10","author":"Olsen","year":"2001","journal-title":"Health Econ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00019053-199915010-00002","volume":"15","author":"Bala","year":"1999","journal-title":"Pharmacoeconomics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","article-title":"ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.3390\/molecules30193867","article-title":"Scutellarein protects against UVB-induced skin injury in a mouse model","volume":"3019","author":"Sun","year":"2025","journal-title":"Molecules"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1681358","DOI":"10.3389\/fimmu.2025.1681358","article-title":"Salvianolic acid B: a promising cardioprotective agent","volume":"16","author":"Shao","year":"2025","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"152927","DOI":"10.1016\/j.bbrc.2025.152927","article-title":"Investigating the anti-atherosclerotic mechanisms of Panax notoginseng saponins through integrated cell experiments, online preparative high-performance liquid chromatography, network pharmacology, molecular docking, and molecular dynamics simulations","volume":"791","author":"Zhang","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B40","unstructured":"Committee on Herbal Medicinal Products (HMPC)\n          \n          \n          \n          2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1186\/s12913-023-09742-8","article-title":"Assessment of the operation status of electronic prescription at community pharmacies in Chengdu, China: a simulated patient study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Health Serv Res."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1696072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:30:15Z","timestamp":1768372215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1696072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2025.1696072"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1696072","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1696072"}}